புவியியல் அட்ரோஃபீ News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from புவியியல் அட்ரோஃபீ. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In புவியியல் அட்ரோஃபீ Today - Breaking & Trending Today

EyeGate Pharmaceuticals Announ - GuruFocus.com


Confirm
-EyeGate signs non-binding letter of intent to acquire Bayon Therapeutics, a private ophthalmic pharmaceutical company developing a novel, vision restoring small molecule platform-
WALTHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) EyeGate Pharmaceuticals, Inc. ( EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system, today announced that Brian M Strem, Ph.D., Co-Founder, Director and former Chief Executive Officer of Okogen, Inc as well as Co-Founder and Managing Director of Bayon Therapeutics, was appointed as permanent President, Chief Executive Officer and board member, effective immediately. He brings strategic expertise, scientific acumen and drug development experience in ophthalmology, otology and regenerative medicine to his new role. ....

Corey Davis , Brianm Strem , Franz Obermayr , Cytori Therapeutics , Cornell University , Okogen Inc , Global Business Development , Global Business Development At Shire Pharmaceuticals , Eyegate Pharmaceuticals Inc , Clinical Development , Business Development , Gate Pharmaceuticals , Chief Executive Officer , Managing Director , Bayon Therapeutics , Stephen From , Executive Chairman , Acting Chief Executive Officer , Intellectual Property , Chief Executive , Sound Pharmaceuticals , Shire Pharmaceuticals , Term Sheet , Retinitis Pigmentosa , Geographic Atrophy , Age Related Macular Degeneration ,

Apellis to Showcase Leadership in Retina at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting


Apellis to Showcase Leadership in Retina at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Nachrichtenquelle: globenewswire
 |  16.04.2021, 18:44  | 
82 
10 accepted abstracts include five oral presentations from pioneering artificial intelligence (AI) collaboration
Presentations support the potential of intravitreal pegcetacoplan, an investigational targeted C3 therapy, as the first treatment for geographic atrophy (GA)
WALTHAM, Mass., April 16, 2021 (GLOBE NEWSWIRE)
Apellis
Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that 10 abstracts were accepted for presentation at the
virtual Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held May 1-7, 2021. These abstracts feature a breadth of data, from presentations that demonstrate ....

United States , Intravitreal Pegcetacoplan , Ursula Schmidt Erfurth , Mark Dole , Drug Administration , Exchange Commission , University Eye Hospital , Apellis Pharmaceuticals Inc , European Medicines Agency , Department Of Ophthalmology , Lancet Glob Health , University Of Vienna , Ophthalmic Image Analysis , Based Quantification , Photoreceptor Maintenance , Geographic Atrophy Secondary , Treatment Effects , Optical Coherence Tomography , Regional Progression , Deep Learning , Open Label , Single Arm Safety Study , Intravitreal Pegcetacoplan Supporting , Geographic Atrophy , Poster Abstract , Macular Degeneration ,